Simultaneous quantification of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry

Walter Loos, Anne-joy Graan, Peter de Bruijn, Ron van Schaik, Mariane Fessem, Mei Lam, RHJ Mathijssen, Erik Wiemer

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)

Abstract

A rapid and sensitive ultra performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS) method has been developed and validated for the simultaneous quantitative determination of dextromethorphan (DM) and its metabolites dextrorphan (DX), 3-methoxymorphinan (3MM) and 3-hydroxymorphinan (3HM), in human lithium heparinized plasma. The extract,on involved a simple liquid-liquid extraction with 1 ml n-butylchloride from 200 mu l aliquots of plasma, after the addition of 20 pi 4% (v/v) ammonium hydroxide and 100 mu l stable labeled isotopic internal standards in acetonitrile. Chromatographic separations were achieved on an Aquity UPLC (R) BEH C(18) 1.7 mu m 2.1 mm x 100 mm column eluted at a flow-rate of 0.250 ml/min on a gradient of acetonitrile. The overall cycle time of the method was 7 min, with elution times of 1.3 min for DX and 3HM, 2.8 min for 3MM and 2.9 min for DM. The multiple reaction monitoring transitions were set at 272 > 215 (m/z), at 258> 133 (m/z), at 258 > 213 (m/z) and at 244 > 157 (m/z) for DM, DX, 3MM and 3HM, respectively. The calibration curves were linear (r(2) >= 0.995) over the range of 0.500-100 nM with the lower limit of quantitation validated at 0.500 nM for all compounds, which is equivalent to 136, 129, 129 and 122 pg/ml for DM, DX, 3MM and 3HM, respectively. Extraction recoveries were constant, but ranged from 39% for DM to 83% for DX. The within-run and between-run precisions were within 11.6%, while the accuracy ranged from 92.7 to 110.6%. The applicability of the bioanalytical method was demonstrated and is currently implemented in a clinical trial to study DM as probe-drug for individualized tamoxifen treatment in breast cancer patients. (C) 2010 Elsevier B.V. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)387-394
Number of pages8
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume54
Issue number2
DOIs
Publication statusPublished - 2011

Cite this